Analysis of BioTime manpower and management performance can provide insight into BioTime stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with BioTime future performance. Check also Trending Equities.
BioTime Management EffectivenessThe company has return on total asset (ROA) of (12.67) % which means that it has lost $12.67 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (39.03) % meaning that it generated substantial loss on money invested by shareholders.
BioTime Workforce Comparison
BioTime is rated below average in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 1,251. BioTime holds roughly 92.0 in number of employees claiming about 7% of stocks in Biotechnology industry.
BioTime Benchmark Summation
|Michael West Co-CEO, Director|
|Brian Culley President CEO, Director|
|Pedro Lichtinger President CEO of Asterias Biotherapeutics|
|Aditya Mohanty Co-President Co-CEO, Director|
|Alfred Kingsley Chairman of the Board|
|Judith Segall Vice President - Administration, Corporate Secretary, Director|
|Russell Skibsted CFO|
|Michael Mulroy Director|
|David Schlachet Independent Director|
|Deborah Andrews Independent Director|
|David Nakasone Director - Investor Relations|
|Neal Bradsher Independent Director|
|Angus Russell Director|
|Cavan Redmond Independent Director|
|Stephen Farrell Independent Director|
|Stephana Patton General Counsel|
|Matt Haines IR Contact Officer|
BioTime employes about 92 people. The company is managed by 17 executives with total tenure of roughly 73 years, averanging almost 4.0 years of service per executive having 5.0 employee per reported executive.
|Revenue Per Employee||56.8 K|
|Revenue Per Executive||307.6 K|
|Net Loss Per Employee||793.2 K|
|Net Loss Per Executive||4.3 M|